ATLANTA — The tetravalent meningococcal conjugate vaccine is now recommended for all 11- to 18-year-olds instead of select age groups, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices voted at its June 27th meeting.
PREVIEW